<--- Back to Details
First PageDocument Content
Pharmaceutical sciences / Pharmacology / Health care / Pharmaceuticals policy / Pharmaceutical industry / Pharmacy / Drugs / Clinical pharmacology / Medicare Part D / Specialty drugs / Prescription drug / Medicare
Date: 2016-02-27 18:42:24
Pharmaceutical sciences
Pharmacology
Health care
Pharmaceuticals policy
Pharmaceutical industry
Pharmacy
Drugs
Clinical pharmacology
Medicare Part D
Specialty drugs
Prescription drug
Medicare

February 2016 Rx Price Watch Report

Add to Reading List

Source URL: www.aarp.org

Download Document from Source Website

File Size: 746,07 KB

Share Document on Facebook

Similar Documents

Healthcare reform in the United States / Health / Federal assistance in the United States / Presidency of Lyndon B. Johnson / Managed care / Medicare / End Stage Renal Disease Program / Medicaid / Fee-for-service / Attachment theory

Announcement of Calendar Year (CYMedicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter and Request for Information

DocID: 1xTu9 - View Document

Medicare Part D stand-alone prescription drug plans for 2018 People who get their health benefits from a Medicare supplement policy or a non-managed care Medicare Advantage plan with no drug coverage may enroll in a stan

DocID: 1tPLN - View Document

Opioids in Medicare Part D: Concerns about Extreme Use and Questionable Prescribing (OEI; 07/17)

DocID: 1ttzb - View Document

Mirror, Mirror on the Wall: Medicare Part D pays needlessly high brand-name drug prices compared with other OECD countries and with U.S. government programs By Marc-André Gagnon, PhD.

DocID: 1th0B - View Document

Coalition of 26 Groups to Congress: Oppose Medicare Part D Rebate Proposals June 21, 2016 Dear Senators and Representatives: In the final months of the Obama Administration, the White House and Congress will engage in an

DocID: 1sahA - View Document